How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

738 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

521. The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose

6 weeks before randomisation : lipid lowering drug other than study medication, Cyclosporine A, medical treatment against obesity (i.e., Orlistat, Sibutramine), oral anticoagulants. Special attention will be paid to the medications that could interfere with the lipid profile (i.e. oral corticosteroids, retinoids, thyroid hormones, thiazide derivative, diuretics, beta-blockers, and hormone replacement therapies). It is recommended not to modify these medications within 6 weeks prior to study

2005 Clinical Trials

522. A Comparative Study of KES524 in Patients With Obesity Disease

scan, HbA1c, TG and HDL-C (secondary endpoints). Condition or disease Intervention/treatment Phase Obesity Drug: Sibutramine Hydrochloride Monohydrate Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment Official Title: A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease Study Start Date : July (...) Clinical Research Dept., Clinical Research Center More Information Go to Layout table for additonal information Identifier: Other Study ID Numbers: KES524-J081-161 First Posted: September 14, 2005 Last Update Posted: January 29, 2010 Last Verified: January 2010 Additional relevant MeSH terms: Layout table for MeSH terms Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Sibutramine Antidepressive Agents Psychotropic Drugs Appetite Depressants Anti

2005 Clinical Trials

523. How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

, tricyclic antidepressant) that might alter gastric emptying Use prednisone or other systemic glucocorticoid drug in the last 3 months Use of any drug for weight-control (e.g. sibutramine, phentermine, orlistat) in the last 3 months Use of any unproven investigational drug within the last 3 months Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2008 Clinical Trials

524. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. (Full text)

Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. To review economic evaluations of weight loss drugs and compare reported incremental cost-effectiveness ratios (ICERs).A literature search was conducted for cost-effectiveness (CEAs) and cost-utility analyses (CUAs) of sibutramine, orlistat and rimonabant.Fourteen unique articles were identified (11 CUAs and 3 CEAs; 9 orlistat, 4 sibutramine and 1 rimonabant). All used diet and exercise as comparator, whereas (...) not incorporated.Published economic evaluations indicate that orlistat, sibutramine and rimonabant are within the range of what is generally regarded as cost-effective. Uncertainty remains about weight loss sustainability, utility gain associated with weight loss and extrapolations from transient weight loss to long-term health benefits. Modeling of head-to-head comparisons and attrition is needed, as are analyses conducted independently of manufacturing companies.

2008 International Journal of Obesity PubMed abstract

525. Pharmacological and surgical treatment of obesity. (Abstract)

Cyclobutanes 0 Lactones 01K63SUP8D Fluoxetine 01ZG3TPX31 Bupropion 0H73WJJ391 Topiramate 30237-26-4 Fructose 95M8R751W8 Orlistat C045TQL4WP Phentermine EC Lipase Q94YYU22B8 Diethylpropion WV5EC51866 sibutramine IM Adult Appetite Depressants therapeutic use Bupropion therapeutic use Cyclobutanes therapeutic use Diethylpropion therapeutic use Fluoxetine therapeutic use Fructose analogs & derivatives therapeutic use Gastric Bypass Gastroplasty Humans Lactones therapeutic use Lipase antagonists

2004 Evidence report/technology assessment (Summary)

526. Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. (Full text)

/m(2) or for those with a BMI of 27 to 30 kg/m(2) and two or more risk factors, who have failed on diet and exercise alone. To date, the U.S. Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine.

2006 Obesity PubMed abstract

527. New drug policy in childhood obesity. (Abstract)

New drug policy in childhood obesity. To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.The paper reviews current and investigational antiobesity drugs.At present, there are only few drugs approved by the Food and Drug Administration (FDA) for the treatment of adult obesity. The most important ones are sibutramine and orlistat. The FDA in the USA approved the latter drug in 2003, and it has recently been

2005 International Journal of Obesity

528. G protein polymorphisms do not predict weight loss and improvement of hypertension in severely obese patients. (Abstract)

were performed blinded to the phenotypic characteristics of the study group. Frequencies of polymorphisms were comparable to those previously published. No polymorphism studied predicted 3-year weight loss or was associated with high blood pressure in severely obese patients after gastric banding. Multivariate analysis of potentially confounding factors such as reoperation rate or use of sibutramine or orlistat revealed similar results (P > 0.1). Regardless of the mechanism(s) involved

2004 Journal of Gastrointestinal Surgery

529. Metabolic syndrome treatment strategies. (Abstract)

antihypertensives, insulin sensitizers, and cholesterol-lowering agents. In addition, two drugs-sibutramine and rimonabant-have been evaluated and produced promising outcomes in the overall management of high-risk patients with metabolic syndrome.

2006 Pharmacotherapy

530. Therapeutic options for modifying cardiometabolic risk factors. (Abstract)

to reduce weight and modify metabolic syndrome components, including sibutramine, orlistat, metformin, and rimonabant. Data from four phase 3 trials suggest that rimonabant, the first cannabinoid receptor inhibitor, modulates cardiometabolic risk factors, both through its impact on body weight and through direct pathways that are not related to weight loss.

2007 American Journal of Medicine

531. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. (Full text)

mechanisms, but only a few drugs have been developed that tap these mechanisms. Orlistat, which blocks intestinal lipase, is one; sibutramine, a serotonin-norepinephrine reuptake inhibitor, is a second. Surgical approaches provide the most dramatic weight loss and have been demonstrated to reduce long-term mortality and reduce the incidence of diabetes.Weight loss can be achieved by many methods, but the surgical procedures appear to be the most durable.

2008 Journal of Clinical Endocrinology and Metabolism PubMed abstract

532. Are mood disorders and obesity related? A review for the mental health professional. (Abstract)

, cardiovascular, diabetes, cortisol, hypertriglyceridemia, sympathetic, family history, stimulant, sibutramine, antiobesity, antidepressant, topiramate, and zonisamide. We evaluated studies of obesity (and related conditions) in persons with mood disorders and of mood disorders in persons with obesity. We also compared studies of obesity and mood disorders regarding phenomenology, comorbidity, family history, biology, and pharmacologic treatment response.The most rigorous clinical studies suggest that (1

2004 Journal of Clinical Psychiatry

533. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. (Abstract)

for diagnosing the metabolic syndrome. Lifestyle modification is the first-line approach to the management of obesity and the metabolic syndrome. However, if patients are unable to achieve a weight loss of 5%-10% of initial body weight and improve cardiometabolic risk factors with lifestyle modification alone, physicians should consider using adjunctive long-term pharmacotherapy. A variety of approved and investigational pharmacologic agents, including sibutramine, orlistat, metformin, and rimonabant, have

2007 American Journal of Cardiology

534. Obesity in Adults

potential benefits and limitations with the patient. Sibutramine (withdrawn) Action - this is a centrally-acting serotonin and noradrenaline reuptake inhibitor which has the effect of promoting satiety and increasing energy expenditure. [ ] Its use has been suspended in the UK amid fears that it increases the risk of heart attacks and strokes. [ ] Some researchers maintain that sibutramine could still be a useful option in patients who do not have pre-existing cardiovascular disease. [ ] Rimonabant (...) (MHRA), Jan 2010 (archived content) ; Unfeasibility of a risk mitigation strategy for sibutramine. Rev Bras Psiquiatr. 2012 Mar34(1):118. ; Medicines and Healthcare products Regulatory Agency (MHRA), Oct 2008 (archived content) ; Efficacy of rimonabant in obese patients with binge eating disorder. Exp Clin Endocrinol Diabetes. 2013 Jan121(1):20-6. doi: 10.1055/s-0032-1329957. Epub 2012 Nov 12. ; NICE Evidence Summary, June 2017 ; A systematic review on use of Chinese medicine and acupuncture

2008 Mentor

535. The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

that may be associated with taking olanzapine. Condition or disease Intervention/treatment Phase Schizophrenia Psychotic Disorders Bipolar Disorder Drug: Sibutramine Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 130 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment Official Title: The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated (...) Bipolar and Related Disorders Body Weight Changes Body Weight Signs and Symptoms Olanzapine Sibutramine Anti-Obesity Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents

2002 Clinical Trials

536. Drug treatment for obesity : We need more studies in men at higher risk of coronary events (Full text)

Drug treatment for obesity : We need more studies in men at higher risk of coronary events 11397730 2001 07 05 2018 11 13 0959-8138 322 7299 2001 Jun 09 BMJ (Clinical research ed.) BMJ Drug treatment for obesity. We need more studies in men at higher risk of coronary events. 1379-80 Despr├ęs J P JP eng Editorial Research Support, Non-U.S. Gov't England BMJ 8900488 0959-8138 0 Appetite Depressants 0 Cholesterol, LDL 0 Cyclobutanes WV5EC51866 sibutramine AIM IM BMJ. 2001 Sep 8;323(7312):576

2001 BMJ : British Medical Journal PubMed abstract

537. Pharmacological intervention: the antiobesity approach. (Abstract)

and sibutramine, are expected shortly for the long-term treatment of obesity. These agents have been shown to be effective in 1-2-year-long studies in obese, non-diabetic patients. They produced significant improvements in weight loss compared with placebos. The efficacy of these obesity management agents has also been demonstrated in short-term studies in patients with type II diabetes. As yet, however, few studies have investigated the long-term effects of these treatments in diabetic patients. Obese (...) group versus 10.4% in the placebo group). Encouraging results have also been reported from studies on orlistat and sibutramine in non-diabetics, with beneficial effects seen for weight loss and other diabetes risk factors. Antiobesity pharmacotherapy therefore appears to offer a realistic option for the prevention of diabetes, although further studies are required to determine its efficacy.

1998 European journal of clinical investigation

538. Modern medical management of obesity: the role of pharmaceutical intervention. (Abstract)

Modern medical management of obesity: the role of pharmaceutical intervention. The medical model of obesity treatment--combining diet, exercise, and behavior modification with antiobesity agents--suffered a setback when fenfluramine and dexfenfluramine were withdrawn from the market because of an association between these medications and valvular regurgitation. The Food and Drug Administration has recently approved sibutramine (Meridia), a norepinephrine and serotonin reuptake inhibitor (...) that was originally developed as an antidepressant, but which has also been shown to reduce weight. In a 1-year placebo-controlled trial, 65% of patients receiving 15 mg sibutramine daily lost more than 5% of their body weight, compared with 29% of patients receiving a placebo; 39% of patients in the sibutramine group lost more than 10% of their body weight, compared with 8% of patients in the placebo group. Health benefits observed in patients receiving sibutramine include reductions in levels of triglycerides

1998 Journal of the American Dietetic Association

539. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. (Full text)

to 159 kg over 1 to 5 years). Weight reduction improved blood pressure, lipid levels, and glucose metabolism and decreased diabetes incidence. The internal validity of the treatment trials was fair to good, and external validity was limited by the minimal ethnic or gender diversity of volunteer participants. No data evaluated counseling harms. Primary adverse drug effects included hypertension with sibutramine (mean increase, 0 mm Hg to 3.5 mm Hg) and gastrointestinal distress with orlistat (1% to 37

2003 Annals of internal medicine PubMed abstract

540. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. (Abstract)

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Weight loss medications are recommended as an adjunct to diet and exercise modification but seem to be prescribed as a monotherapy by many physicians. This practice is likely to be associated with suboptimal weight loss.This 1-year, randomized trial compared the effects of sibutramine hydrochloride used alone (ie, the drug-alone group) to sibutramine plus group lifestyle modification, prescribed

2001 Archives of internal medicine Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>